Novavax, Inc.

Good day, everyone, and welcome to the NEVAVAC second quarter 2021 financial and operating results. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press the star, then one. Please note that this event is being recorded. I'd now like to turn the conference over to Sylvia Taylor, Senior Vice President, Corporate Affairs and Investor Relations. Please go ahead.

Thanks, Cole. Good afternoon, everyone, and thank you to all of you who have joined today's call to discuss our second quarter 2021 operational highlights and financial results. A press release announcing our results is currently available on our website at Novavax.com, and an audio archive of this conference call will be available on our website later today. We've also posted the slides we are using during today's call under events in the investor section of our website. Joining me today is Stan Erck, President and CEO, who will provide an overview of our progress in the second quarter, our supply commitments, our regulatory timelines, as well as updates on manufacturing. Dr. Philip Dubovsky, Chief Medical Officer, will discuss developments for our COVID-19 program, and John Trezino, Chief Commercial Officer, Chief Business Officer, and Interim Chief Financial Officer, will provide an update on our financial results for the quarter. Additionally, Dr. Greg Glenn, President of R&D, will be available for the Q&A section at the end of today's call. Before we begin with prepared remarks, I need to remind you that we will be making forward-looking statements during this teleconference, which are based on our current projections and beliefs. For example, statements relating to future financial or business performance, conditions or strategy, including expectations regarding revenue, operating expenses, cash usage, clinical development of our vaccine candidates, timing of future regulatory filings and actions, and other anticipated milestones are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties which change over time, and actual results could differ materially from what is described in such statements. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. I would now like to hand the call over to Stan. For those of you following the accompanying slides, please turn to slide three.

And thank you, Sylvia. And thanks to everyone for joining us today. As we start this presentation today, we can note that through the development of vaccines and treatments today, significant progress has been made to combat the COVID-19 pandemic.